# A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

> **NCT02734693** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 132 (actual)

## Conditions studied

- Attention-Deficit Hyperactivity Disorder (ADHD)

## Interventions

- **DRUG:** dasotraline 4mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02734693
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-30
- **Primary completion:** 2017-02-28
- **Final completion:** 2017-02-28
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2020-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02734693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02734693, "A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02734693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*